This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
by Zacks Equity Research
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
LabCorp Diagnostics Shows Robust Growth Amid Price Declines
by Zacks Equity Research
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor
by Zacks Equity Research
Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor
Robust Sales Growth Makes These 5 Stocks Worth Buying Now
by Swayta Shah
Sales growth provides investors an insight into product demand and pricing power.
LH vs. XRAY: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. XRAY: Which Stock Is the Better Value Option?
LabCorp (LH) Closes Envigo Swap Deal, Expands in CRO Space
by Zacks Equity Research
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
Why Is LabCorp (LH) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses
by Zacks Equity Research
LabCorp's (LH) diagnostics business grows organically despite additional price reductions.
LH or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. ALGN: Which Stock Is the Better Value Option?
LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates
by Urmimala Biswas
Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
What's in Store for Align Technology (ALGN) in Q1 Earnings?
by Zacks Equity Research
Higher Invisalign case volume, solid show by Clear Aligner segment and anticipated sturdy growth at Scanner and Service business are likely to support Align Technology (ALGN) in Q1. However, operating expenses are likely to act as dampeners.
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
Should Value Investors Consider Laboratory Corporation (LH)?
by Zacks Equity Research
Laboratory Corporation (LH) stock may be a good choice for value-oriented investors right now from multiple angles.
Why Is LabCorp (LH) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
LabCorp (LH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 1.61% and 0.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
by Zacks Equity Research
LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.
LabCorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp Rides on Covance Business Amid Reimbursement Woes
by Zacks Equity Research
Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.
LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite
by Zacks Equity Research
LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.